

2018 Diabetic Gastroparesis Drug Development-Pipeline Analysis Report

https://marketpublishers.com/r/2F5024FA186EN.html

Date: May 2018

Pages: 0

Price: US\$ 999.00 (Single User License)

ID: 2F5024FA186EN

Abstracts

With an estimated 3-5 million people in the US suffering from gastroparesis, with young population around 34 years being more susceptible, the Diabetic Gastroparesis presents significant market opportunities of around \$5 billion to \$6 billion. Metoclopramide is the only FDA approved drug for treatment of the disease and accordingly, several researchers are focusing on developing new treatment options for the disease. Diabetic Gastroparesis is a GI disorder in which the stomach takes longer periods for emptying the contents.

Around 15 companies and universities are focusing on developing treatment options for Diabetic gastroparesis.

To assist investigators and funding and regulatory organizations, VPA Research has come up with a comprehensive report on Diabetic gastroparesis pipeline. The report provides insights into different therapeutic candidates in preclinical, research, discovery, NDA/IND, pre registration, phase 1, phase 2, and phase 3 trials). Drugs under development directly and through combination with other drugs are also included.

Current status, developmental phase, participating companies and entities, recent developments, orphan drug/fast track/other designations, drug class are provided for each Diabetic gastroparesis pipeline product. Mechanism of Action and the target area of the pipeline product are also provided. Further, clinical and preclinical trials along with results of the trials are also included in the report.

In addition to complete details of each product, the report provides key trends in Diabetic gastroparesis pipeline studies. The products under development are categorized according to their development phase, mechanism and company to provide



detailed insights into the type of drugs being developed and the stages of development.



Contents

1 TABLE OF CONTENTS

- 1.1 List of Figures
- 1.2 List of Tables

2 DIABETIC GASTROPARESIS PIPELINE ANALYSIS

- 2.1 Disease and Pipeline Overview
- 2.2 Diabetic Gastroparesis Pipeline Snapshot
- 2.3 Diabetic Gastroparesis Pipeline by Phase
- 2.4 Diabetic Gastroparesis Pipeline by Company
- 2.5 Diabetic Gastroparesis Pipeline by Mechanism of Action

3 DIABETIC GASTROPARESIS- COMPANY WISE PIPELINE ANALYSIS

Allergan

EndoLogic

ETX Pharma

Evoke Pharma

Shire-Movetis

Takeda Pharmaceutical

Theravance Biopharma

4 DIABETIC GASTROPARESIS R&D PIPELINE SNAPSHOTS

Drug wise Pipeline Details

Therapeutic Candidate Name

Originator

Co-Developer/License Partner

Orphan Drug Designation

Development Phase

Mechanism of Action

Current Status

Ongoing Clinical Trial Details

5 RECENT DEVELOPMENTS IN DIABETIC GASTROPARESIS PIPELINE



6 APPENDIX

- 6.1 About VPA Research
- 6.2 Sources and Research Methodology



List Of Figures

LIST OF FIGURES

- Figure 1: Diabetic Gastroparesis Pipeline by Phase, H1- 2018
- Figure 2: Diabetic Gastroparesis Pipeline by Companies, H1- 2018
- Figure 3: Company Wise Pipeline Drug Phases, H1- 2018
- Figure 4: Diabetic Gastroparesis Pipeline by Mechanism of Action, H1- 2018
- Figure 5: Mechanism Wise Pipeline Drug Phases, H1-2018



List Of Tables

LIST OF TABLES

Table 1: Diabetic Gastropare	esis Pipeline b	ov Phase	. H1-	2018
------------------------------	-----------------	----------	-------	------

- Table 2: Diabetic Gastroparesis Pipeline by Companies, H1- 2018
- Table 3: Diabetic Gastroparesis Pipeline by Mechanism of Action, H1- 2018
- Table 4: Allergan Diabetic Gastroparesis Pipeline, May 2018
- Table 5: EndoLogic Diabetic Gastroparesis Pipeline, May 2018
- Table 6: ETX Pharma Diabetic Gastroparesis Pipeline, May 2018
- Table 7: ETX Pharma Diabetic Gastroparesis Pipeline, May 2018
- Table 8: Evoke Pharma Diabetic Gastroparesis Pipeline, May 2018
- Table 9: Shire-Movetis Diabetic Gastroparesis Pipeline, May 2018
- Table 10: Takeda Pharmaceutical Diabetic Gastroparesis Pipeline, May 2018



I would like to order

Product name: 2018 Diabetic Gastroparesis Drug Development- Pipeline Analysis Report

Product link: https://marketpublishers.com/r/2F5024FA186EN.html

Price: US\$ 999.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer

Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/2F5024FA186EN.html

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:	
Last name:	
Email:	
Company:	
Address:	
City:	
Zip code:	
Country:	
Tel:	
Fax:	
Your message:	
	**All fields are required
	Custumer signature

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at https://marketpublishers.com/docs/terms.html

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970